Physician profile
Marat Zeltsman
NPI 1497742258
$787.78
in general payments reported to CMS, 2019-2025
14 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $30.38 · 2022: $67.33 · 2023: $143 · 2024: $199 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $180.41 | 2019-2025 | Gardasil 9, Vaxelis, Enflonsia |
| Cranial Technologies, INC | $156.77 | 2019-2025 | Doc Band |
| Sanofi Pasteur INC. | $140.95 | 2023-2025 | |
| Sobi, INC | $61.75 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $56.74 | 2023-2024 | Flumist Quadrivalent |
| Sanofi-Aventis U.S. LLC | $48.60 | 2024-2025 | |
| Verrica Pharmaceuticals INC. | $35.90 | 2024 | Ycanth |
| Pfizer INC. | $17.86 | 2019 | |
| Alk-Abello, INC | $17.27 | 2025 | Neffy |
| Phadia US INC. | $16.92 | 2022 | |
| Shire North American Group INC | $15.57 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.74 | 2019 | |
| Corium, LLC | $12.71 | 2025 | Azstarys |
| Novo Nordisk INC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marat Zeltsman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.